TD Cowen initiated coverage of Amylyx (AMLX) with a Buy rating and no price target The company’s lead asset avexitide is a GLP-1 receptor antagonist in development for post-bariatric hypoglycemia, the analyst tells investors in a research note. The firm says its key opinion leaders are optimistic for Phase III success and eventual uptake based on the prior Phase II data. TD sees Amylyx shares as undervalued for the potential of avexitide in post-bariatric hypoglycemia alone.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $8 from $7 at Mizuho
- Positive Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising HELIOS Trial Results for AMX0035
- Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges
- Amylyx announces results from Phase 2 HELIOS trial of AMX0035
- Amylyx price target raised to $16 from $12 at H.C. Wainwright